EGFR and non-small cell lung carcinoma: Our findings suggest the lazertinib has been well handled, having reactions seen often in patients with NSCLC who had both activation and Tyrosine kinase inhibitor- (TKI-) resistant mutations in epidermal growth factor receptor (EGFR).